BUZZ-Ascletis hits record high on weight loss drug's potential in early trial
Reuters
Aug 13
BUZZ-Ascletis hits record high on weight loss drug's potential in early trial
** Ascletis Pharma1672.HK rises 9.7% to record high of HK$15.95; set for fifth straight session of gains
** Pharmaceutical products maker says its ASC47 shows greater efficacy with tirzepatide
** Notes pre-clinical data builds on evidence of ASC47's potential as important therapeutic approach to treat obesity
** Adds ASC47 low dose and tirzepatide combination shows 87% more relative weight loss vs tirzepatide monotherapy
** ASC47 is a muscle-preserving weight loss drug candidate for treatment of obesity
** YTD, stock surges 426.6%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.